PAR-1: A Potential Drug Target for Pancreatic Cancer (G145624)

Target Name: PWAR1

NCBI ID: G145624

PWAR1

Other Name(s): PAR-1 | Prader Willi/Angelman region RNA 1 | PAR1 | D15S227E

PAR-1: A Potential Drug Target for Pancreatic Cancer

PAR-1 (Pancreatic cancer associated with the Ku70 gene) is a protein that is expressed in pancreatic cancer cells. It is a known gene that has been associated with the development of pancreatic cancer. PPAR-1 has also been identified as a potential drug target in the treatment of pancreatic cancer.

PAR-1 is a transducing RNA (RNA-mediated transport) gene, which plays an important role in tumorigenesis. It is expressed in a variety of cancers, including pancreatic, lung, breast, and ovarian cancers. In pancreatic cancer, the expression level of PAR-1 is high, and its expression level is closely related to the severity and prognosis of the disease.

The protein encoded by the PAR-1 gene is a transducing RNA that transports materials within cells. In cancer cells, the PAR-1 protein is often expressed at high levels, making it a potential drug target.

Scientists have discovered that the PAR-1 protein has great potential in treating pancreatic cancer. For example, PAR-1 inhibitors have been shown to inhibit the growth and spread of pancreatic cancer cells. In addition, PAR-1 inhibitors can also inhibit the angiogenesis of tumor cells, thus providing a new approach for the treatment of pancreatic cancer.

In addition, the PAR-1 gene is also considered an important biomarker for the diagnosis and prognosis of pancreatic cancer. Since the expression level of PAR-1 protein is high in pancreatic cancer, the severity and prognosis of pancreatic cancer can be assessed by detecting the level of PAR-1 protein.

Overall, the PAR-1 protein is a potential drug target for the treatment of pancreatic cancer. Future research will continue to further investigate the role of PAR-1 protein in the treatment of pancreatic cancer and provide new guidance for clinical practice.

Protein Name: Prader Willi/Angelman Region RNA 1

The "PWAR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PWAR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets